Fig. 7

MAPK4-shRNA pre-treatment protects mice against LPS-induced ALI. a Schematic diagram showing WT mice were treated with i.t. 10ug MAPK4-shRNA or control vector, then mice were administered with i.p. 10 mg/kg LPS in day 0, respectively. b Lung tissues (n = 5–6) were obtained in day 0 and the relative expression of MAPK4 was detected by Real-time PCR assay and Western blot. c Lung tissues (n = 5–6) were obtained in day 2 and the lung wet-dry ratio were detected. d The pathology of lung tissues was analyzed by HE staining in day 2. Arrows indicate infiltrated cells. Scale bar = 50 μm. e The mRNA levels of IL-1β, TNF-α, IL-4 and IL-10 were detected by Real-time PCR assay in day 2. f, g The expressions of ERK, p-ERK, AKT, p-AKT, p38 MAPK, p-p38 MAPK, JNK and p-JNK were detected and calculated by Western blot in day 2. h WT mice (n = 6) were treated with i.t. 10ug MAPK4-shRNA or control vector, then mice were administered with i.p. 15 mg/kg LPS. The survival ratio of mice was recorded, respectively. Data were presented as the mean ± SEM. *p < 0.05, **p < 0.01